The therapeutic use of antibodies for malignancy

Transfusion Clinique et Biologique

Volumn 8, Issue 3, 2001, Pages 255-259

  Johnson, P W M ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cancer; Immunotherapy; Lymphoma; Monoclonal antibody

Indexed keywords

ANTIBODY CONJUGATE; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; B CELL LYMPHOMA; CANCER; CANCER CELL; CONFERENCE PAPER; HUMAN; HUMAN CELL; IMMUNOTHERAPY;

EID: 0034925360     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1246-7820(01)00182-3     Document Type: Conference Paper

References (36)

1. Human antibodies by design
2. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
3. FcRn: The MHC class I-related receptor that is more than an IgG transporter
4. Regulation of the complement membrane attack pathway
5. Transduction of cytotoxic signals in natural killer cells: A general model of fine tuning between activatory and inhibitory pathways in lymphocytes
6. Fc receptors are required in passive and active immunity to melanoma
7. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
8. Effects of campath-1 antibodies iv vivo in patients with lymphoid malignancies: Influence of antibody isotype
9. Campath-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
10. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
11. Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: Results of a phase III study
12. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2
13. Monoclonal antibody therapy of B-cell lymphomas: Signalling activity on tumor cells appears more important than recruitment of effectors
14. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
15. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
16. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
17. Rituximab dose-escalation trial in chronic lymphocytic leukemia
18. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
19. Mabthera (rituximab) plus chop is superior to chop alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
20. Radioimmunotherapy of B-cell lymphoma: The importance of antibody-specificity in determining successful treatment of established disease
21. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
22. Radioimmunotherapy with iodine-(131-I)-tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
23. I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): Clinical and molecular remissions
24. TM radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL
25. Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
26. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
27. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
28. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
29. Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity
30. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
31. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
32. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies
33. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interaction
34. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
35. A stimulating new target for cancer immunotherapy
36. Enhancement of anti-tumor immunity by CTLA-4 blockade